Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Penumbra

3 Medical Device Stocks Giving Investors a Different Healthcare Play

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback

Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback

Although a seemingly inopportune acquisition appears to have cost Boston Scientific dearly, the current valuation of BSX stock may be too enticing to pass up.

Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Boston Scientific's pending trial results could help to drive sales growth for years to come after lower-than-expected sales forecasts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini S&P futures (ESH26 ) rose +0.24%, and March E-mini Nasdaq futures...

This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

3 Mid-Cap Medical Stocks Outperforming the Market

Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.

inkl

Read news from The Economist, FT, and more,
with one subscription

Scotland launches 'world first' project to protect people who self-harm

Scotland launches 'world first' project to protect people who self-harm

A new strategy to support people who self-harm, thought to be the first of its kind in the world, has been backed by funding of £1.5m.

The National (Scotland)

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Penumbra's Return on Invested Capital Insights

Penumbra's Return on Invested Capital Insights

Pulled from Benzinga Pro data, Penumbra (NYSE:PEN) posted Q1 earnings of $79.00 thousand, an increase from Q4 of 100.32%. Sales dropped to $203.90 million, a 0.06% decrease between quarters.

What 4 Analyst Ratings Have To Say About Penumbra

What 4 Analyst Ratings Have To Say About Penumbra

Analysts have provided the following ratings for Penumbra (NYSE:PEN) within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Penumbra: Q1 Earnings Insights

Penumbra (NYSE:PEN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Penumbra missed estimated earnings by 116.67%, reporting an EPS of $-0.01 versus an estimate of $0.06.

Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2022

Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%

Penumbra Inc (NYSE:PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4% (31.1%) to $113.6 million. Revenue from sales of neuro products grew 13.3% (14.1%) to $90.4 million. The gross margin was 61.5%,…

Penumbra's Return on Invested Capital Insights

Benzinga Pro data, Penumbra (NYSE:PEN) reported Q4 sales of $204.01 million. Earnings fell to a loss of $24.63 million, resulting in a 406.72% decrease from last quarter. In Q3, Penumbra earned $8.03 million and total sales reached $190.12 million.

Get all your
news in one place.

100's of premium titles.
One news app.

Recap: Penumbra Q4 Earnings

Penumbra (NYSE:PEN) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Penumbra missed estimated earnings by 54.55%, reporting an EPS of $0.1 versus an estimate of $0.22.

1

People

202,803 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

398,533 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play